A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children's Oncology Group.

ABSTRACT:

Background

Survival for patients with high-risk neuroblastoma remains poor despite current-era multimodality treatment that includes postconsolidation GD2-directed immunotherapy. Given the promising responses in patients who receive dinutuximab-based chemoimmunotherapy in the relapsed setting, the Children's Oncology Group ANBL19P1 study evaluated the feasibility of administering irinotecan, temozolomide, dinutuximab, and sargramostim after frontline consolidation with tandem autologous stem cell transplantation (ASCT).

Methods

Patients with high-risk neuroblastoma who received induction therapy followed by tandem ASCT and had no evidence of progressive disease (PD) were eligible. Treatment included five 28-day cycles of temozolomide and irinotecan (days 1-5), dinutuximab (d

SUBMITTER: Desai AV 

PROVIDER: S-EPMC12796553 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature